ArticleCureus2026
JAK2-Positive Myeloproliferative Neoplasm: Polycythaemia Vera Presenting As Budd-Chiari Syndrome.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Budd-Chiari syndrome (BCS), caused by hepatic venous outflow obstruction, is a critical diagnosis often masking an underlying myeloproliferative neoplasm (MPN). We present the case of a 33-year-old female whose diagnosis was driven by hepatic decompensation rather than typical haematological symptoms of MPN. Initial imaging confirmed the anatomical pathology, revealing chronic BCS on computed tomography (non-visualised hepatic veins, hepatic vein stenosis, and classic caudate lobe hypertrophy). The subsequent work-up noted a paradoxical haematological picture (significant neutrophilic leucocytosis (up to 55,570 cells/mm³) and relative thrombocytosis) despite splenomegaly and portal hypertension. This finding, combined with the CT evidence, prompted definitive genetic screening, which confirmed the diagnosis of an MPN by detecting the JAK2 exon 14 c.1849G>T (p.Val617Phe) mutation (variant allele frequency of 79.2%). This case underscores the importance of utilising radiological evidence in the initial stages and recognising the combination of an atypical blood picture alongside hepatic decompensation as a key indicator for an underlying MPN, allowing for prompt molecular diagnosis and targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.